PRINCETON, N.J., Feb. 1, 2008 (PRIME NEWSWIRE) -- Barrier Therapeutics, Inc. (Nasdaq:BTRX), a pharmaceutical company that develops and markets dermatology products, today announced that it will display key scientific poster presentations at the American Academy of Dermatology (AAD) 66th Annual Meeting to be held February 1 through February 5, 2008 in San Antonio, Texas.
"We are pleased to present positive clinical data at this year's AAD meeting that shows the promise of pramiconazole, which we are developing for both acute and chronic fungal infections," stated Geert Cauwenbergh, Ph.D., Chief Executive Officer of Barrier Therapeutics. "We are also very encouraged by the clinical results from a study of Hivenyl that shows this antihistamine may be effective in reducing or eliminating the annoying symptoms of itch without sedating effects."
The poster presentations are entitled:
-- "Pramiconazole, a novel oral antifungal agent, effectively treats Pityriasis versicolor -- results of a dose finding clinical study"; Poster Number: 1704
-- "Oral vapitadine, a new non-sedating antihistamine, relieves itch associated with atopic dermatitis"; Poster Number: 601; current product candidate referred to as Hivenyl(tm)
Members of Barrier Therapeutics' development team will be in attendance to discuss results outlined in the poster presentations during this year's annual AAD meeting. To view these posters in their entirety, please visit the Press Release section of Barrier Therapeutics' website at http://www.barriertherapeutics.com.
Barrier Therapeutics' booth (#3527) will be located in Exhibit Hall B of the Henry B. Gonzalez Convention Center, San Antonio, Texas.
More information on the American Academy of Dermatology Annual Meeting can be found at http://www.aad.org.
About Barrier Therapeutics
Barrier Therapeutics, Inc. is a pharmaceutical company focused on the development and commercialization of products in the field of dermatology. Barrier Therapeutics currently markets three pharmaceutical products in the United States: Xolegel(r) (ketoconazole, USP) Gel, 2%, for seborrheic dermatitis; Vusion(r) (0.25% miconazole nitrate, 15% zinc oxide, 81.35% white petrolatum) Ointment, for diaper dermatitis complicated by documented candidiasis; and Solage(r) (mequinol 2.0%, tretinoin 0.01%) Topical Solution, for solar lentigines. Barrier Therapeutics has other product candidates in various stages of clinical development for the treatment of a range of dermatological conditions, including onychomycosis, psoriasis, acne, skin allergies, and superficial fungal infections. The company is headquartered in Princeton, New Jersey and has wholly-owned subsidiaries in Geel, Belgium. More information about Barrier Therapeutics can be found on its corporate website at: www.barriertherapeutics.com.
Xolegel, Vusion and Solage are trademarks of Barrier Therapeutics, Inc.
Safe Harbor Statement
In addition to historical facts or statements of current condition, this press release contains forward-looking statements within the meaning of the "Safe Harbor" provisions of The Private Securities Litigation Reform Act of 1995, including statements regarding the potential attributes of the Company's Pramiconazole and Hivenyl product candidates. Forward-looking statements provide Barrier's current expectations or forecasts of future events. Barrier's performance and financial results could differ materially from those reflected in these forward-looking statements due to the marketplace acceptance of Barrier's products, Barrier's ability to execute its commercial and clinical strategy, the decisions of regulatory authorities, the results of clinical trials and strategic decisions regarding its pipeline, general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries generally. For a discussion of these and other risks and uncertainties that may effect the forward-looking statements, please see the risk factors in the company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2007 which is on file with the Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Barrier undertakes no obligation to update publicly any forward-looking statement.
In addition, please note that success in clinical trials does not mean that subsequent trials will confirm earlier findings. No assessment of the efficacy or safety of any product candidate can be considered definitive until all clinical trials needed to support a submission for marketing approval are complete.
CONTACT: Barrier Therapeutics, Inc.
Anne M. VanLent, EVP & CFO
(609) 945-1202
Lazar Partners Ltd.
Investor Relations
Gregory Gin
(212) 867-1762
